title: Real-World Sustained Virologic Response Rates of Sofosbuvir-Containing Regimens in Patients Coinfected With Hepatitis C and HIV.
abstract: Patients with hepatitis C virus (HCV) with or without human immunodeficiency virus (HIV) achieve high sustained virological response (SVR) rates on sofosbuvir (SOF)-containing regimens in clinical trials. Real world data on patients coinfected with HCV and HIV treated with SOF-based regimens are lacking.
  
  
  
  This observational cohort study included HIV/HCV-coinfected adults with genotype 1 HCV who initiated treatment with a SOF-containing regimen between December 2013 and December 2014 (n = 89) at the Mount Sinai Hospital or the Brooklyn Hospital Center. The primary outcome was SVR at 12 weeks after the end of treatment. The secondary outcomes were risk factors for treatment failure, serious adverse events, and side effects. A post hoc per protocol analysis of SVR was performed on patients who completed treatment and follow-up.
  
  
  
  In an intention-to-treat analysis, SVR rates were 76% (31/41) for simeprevir (SMV)/SOF, 94% (16/17) for SMV/SOF/ribavirin (RBV), and 52% (16/31) for SOF/RBV. The SVR rates of SMV/SOF/RBV and SMV/SOF did not differ significantly in this small study (P = .15). However the SVR rate of SMV/SOF/RBV was higher than that of SOF/RBV (P < .01). In a per protocol analysis, SMV/SOF/RBV had a higher SVR rate than SOF/RBV: 100% (16/16) vs 57% (16/28) (P < .01). The most commonly reported adverse effects were rash, pruritus, fatigue, and insomnia. One patient who had decompensated cirrhosis prior to treatment initiation died after receiving SMV/SOF.
  
  
  
  SMV/SOF ± RBV is an effective option with minimal adverse effects for most HIV-positive patients with genotype 1 HCV. SMV should be used with caution in patients with decompensated cirrhosis.
authors.affiliation: Division of Infectious Diseases, Icahn School of Medicine at Mount Sinai.
authors.forename: David
authors.initials: D
authors.lastname: Del Bello
authors.affiliation: Department of Pharmacotherapy, Brooklyn Hospital Center.
authors.forename: Agnes
authors.initials: A
authors.lastname: Cha
authors.affiliation: Department of Pharmacotherapy, Brooklyn Hospital Center.
authors.forename: Maria
authors.initials: M
authors.lastname: Sorbera
authors.affiliation: Division of Liver Diseases.
authors.forename: Kian
authors.initials: K
authors.lastname: Bichoupan
authors.affiliation: Department of Medicine, Icahn School of Medicine at Mount Sinai.
authors.forename: Calley
authors.initials: C
authors.lastname: Levine
authors.affiliation: Division of Liver Diseases.
authors.forename: Erin
authors.initials: E
authors.lastname: Doyle
authors.affiliation: Faculty Practice Associates, Mount Sinai Hospital.
authors.forename: Alyson
authors.initials: A
authors.lastname: Harty
authors.affiliation: Division of Liver Diseases.
authors.forename: Neal
authors.initials: N
authors.lastname: Patel
authors.affiliation: Division of Infectious Diseases, Icahn School of Medicine at Mount Sinai.
authors.forename: Michel
authors.initials: M
authors.lastname: Ng
authors.affiliation: Department of Medicine, Icahn School of Medicine at Mount Sinai.
authors.forename: Donald
authors.initials: D
authors.lastname: Gardenier
authors.affiliation: Division of Liver Diseases.
authors.forename: Joseph
authors.initials: J
authors.lastname: Odin
authors.affiliation: Division of Liver Diseases.
authors.forename: Thomas D
authors.initials: TD
authors.lastname: Schiano
authors.affiliation: Division of Infectious Diseases, Icahn School of Medicine at Mount Sinai.
authors.forename: Daniel S
authors.initials: DS
authors.lastname: Fierer
authors.affiliation: Division of Infectious Diseases, Brooklyn Hospital Center.
authors.forename: Leonard
authors.initials: L
authors.lastname: Berkowitz
authors.affiliation: Division of Liver Diseases.
authors.forename: Ponni V
authors.initials: PV
authors.lastname: Perumalswami
authors.affiliation: Division of Liver Diseases, Division of Infectious Diseases, Icahn School of Medicine at Mount Sinai, New York City, New York.
authors.forename: Douglas T
authors.initials: DT
authors.lastname: Dieterich
authors.affiliation: Division of Liver Diseases.
authors.forename: Andrea D
authors.initials: AD
authors.lastname: Branch
mesh_terms: D000998:Antiviral Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D005260:Female; D015658:HIV Infections / Q000188:drug therapy* / Q000453:epidemiology / Q000821:virology*; D015497:HIV-1; D016174:Hepacivirus; D006526:Hepatitis C / Q000188:drug therapy* / Q000453:epidemiology / Q000821:virology*; D006801:Humans; D008297:Male; D008875:Middle Aged; D009519:New York City / Q000453:epidemiology; D012307:Risk Factors; D000069616:Simeprevir / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D000069474:Sofosbuvir / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D016896:Treatment Outcome; D019562:Viral Load
chemical_list: D000998:Antiviral Agents; D000069616:Simeprevir; D000069474:Sofosbuvir
keywords: HIV; hepatitis C; simeprevir; sofosbuvir